Sanofi Gains Regulatory Approval for Expansion at Site in Ireland - - BioPharm International

ADVERTISEMENT

Sanofi Gains Regulatory Approval for Expansion at Site in Ireland



Sanofi’s subsidiary Genzyme has received approval from FDA and EMA for a second operation for a fill–finish product at its Waterford, Ireland, manufacturing plant.

With this approval, Genzyme has nearly doubled its ability to fill–finish Myozyme and Lumizyme (alglucosidase alfa) produced at the 4000-L bioreactor scale. Genzyme also will begin the process to secure FDA and EMA approvals to fill–finish additional products in the second suite, with the long-term goal to use the Waterford site as a fill–finish platform across its portfolio of products.

Genzyme’s Waterford facility has been in operation for more than 10 years, and a $150-million expansion was completed earlier this year. The Waterford manufacturing site employs over 500 people and is considered Genzyme’s center of excellence for aseptic manufacturing.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Baxter Issues Recall Due to Particulate Matter
July 11, 2014
Hospira Issues Recall Due to Mold Contamination
July 11, 2014
EMA Recommends 39 Drugs in First Half of 2014
July 10, 2014
Biotech Industry Forms International Council
July 10, 2014
FDA Publishes Guidance on ANDA Submissions
July 10, 2014
Author Guidelines

Click here